Exhibit
      31.2


Provectus
      Pharmaceuticals, Inc.


Certification
      Pursuant to Rule 13a-14(a)


Section
      302 Certification





I,
      Peter
      R. Culpepper, the Chief Financial Officer of Provectus Pharmaceuticals, Inc.,
      certify that:





1. 
      I have reviewed this annual report on Form 10-KSB of Provectus Pharmaceuticals,
      Inc.;





2.
       Based on my knowledge, this report does not contain any untrue statement
      of a material fact or omit to state a material fact necessary to make the


statements
      made, in light of the circumstances under which such statements were made,
      not
      misleading with respect to the period covered by this report;





3.
       Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material respects
      the
      financial condition, results of operations and cash flows of the small business
      issuer as of, and for, the periods presented in this report;





4.
       The small business issuer's other certifying officer(s) and I are
      responsible for establishing and maintaining disclosure controls and procedures
      (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small
      business issuer and have:





a) 
      Designed such disclosure controls and procedures, or caused such disclosure
      controls and procedures to be designed under our supervision, to ensure that
      material information relating to the small business issuer, including its
      consolidated subsidiaries, is made known to us by others within those entities,
      particularly during the period in which this report is being
      prepared;





b ) 
      Evaluated the effectiveness of the small business issuer's disclosure controls
      and procedures and presented in this report our conclusions about the
      effectiveness of the disclosure controls and procedures, as of the end of the
      period covered by this report based on such evaluation;





c) 
      Disclosed in this report any change in the small business issuer's internal
      control over financial reporting that occurred during the small business
      issuer's most recent fiscal quarter that has materially affected, or is
      reasonably likely to materially affect, the small business issuer's internal
      control over financial reporting; and





5.
      The
      small business issuer's other certifying officers and I have disclosed, based
      on
      our most recent evaluation of internal control over financial reporting, to
      the
      small business issuer's auditors and the audit committee of the small business
      issuer's board of directors (or persons performing the equivalent
      functions):




a) 
      All significant deficiencies and material weaknesses in the design or operation
      of internal control over financial reporting which are reasonably likely to
      adversely affect the small business issuer's ability to record, process,
      summarize and report financial information; and





b) 
      Any fraud, whether or not material, that involves management or other employees
      who have a significant role in the small business issuer's internal control
      over
      financial reporting.








**PROVECTUS
                PHARMACEUTICALS, INC.**Date: March
                29, 2006
              By:
              /s/ Peter
                R. CulpepperPeter
                R. CulpepperTitle: 
                Chief Financial
                Officer